A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
Year: 2003
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Leukemia Research
Authors: Francis J Giles, Roberto Rodriguez, Daniel Weisdorf, John R Wingard, Paul J Martin, Thomas R Fleming, Stuart L Goldberg, Elias J Anaissie, Brian J Bolwell, Nelson J Chao, Thomas C Shea, Mark M Brunvand, William Vaughan, Finn Petersen, Mark Schubert, Hillard M Lazarus, Richard T Maziarz, Margarida Silverman, Roy A Beveridge, Rebecca Redman, Janis G Pulliam, Patricia Devitt-Risse, Henry J Fuchs, David D Hurd
Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, City of Hope, University of Minnesota, University of Florida Health, University of Florida, Fred Hutch Cancer Center, University of Washington, Rutgers, The State University of New Jersey, Hackensack University Medical Center, University of Arkansas for Medical Sciences, Cleveland Clinic, Duke University, University of North Carolina at Chapel Hill, University of Alabama at Birmingham, University of Utah, University of Utah Hospital, Seattle Cancer Care Alliance, Case Western Reserve University, Oregon Health & Science University, University of Iowa, University of Iowa Hospitals and Clinics, Inova Fairfax Hospital, Wake Forest University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2002013014